311 related articles for article (PubMed ID: 33579805)
1. Quantitative
Ortega C; Wong RKS; Schaefferkoetter J; Veit-Haibach P; Myrehaug S; Juergens R; Laidley D; Anconina R; Liu A; Metser U
J Nucl Med; 2021 Oct; 62(10):1406-1414. PubMed ID: 33579805
[TBL] [Abstract][Full Text] [Related]
2. Visual and whole-body quantitative analyses of
Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
[TBL] [Abstract][Full Text] [Related]
3.
Sharma R; Wang WM; Yusuf S; Evans J; Ramaswami R; Wernig F; Frilling A; Mauri F; Al-Nahhas A; Aboagye EO; Barwick TD
Radiother Oncol; 2019 Dec; 141():108-115. PubMed ID: 31542317
[TBL] [Abstract][Full Text] [Related]
4. Prediction of
Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
7. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
8.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
9. Is SUVmax a useful marker for progression-free survival in patients with metastatic GEP-NET receiving
Teker F; Elboga U
Hell J Nucl Med; 2021; 24(2):122-131. PubMed ID: 34352047
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of somatostatin receptor expressing tumor volume calculated from
Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
[TBL] [Abstract][Full Text] [Related]
11. Radiomics-Based Texture Analysis of
Atkinson C; Ganeshan B; Endozo R; Wan S; Aldridge MD; Groves AM; Bomanji JB; Gaze MN
Front Oncol; 2021; 11():686235. PubMed ID: 34408979
[TBL] [Abstract][Full Text] [Related]
12. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors.
Menon BK; Kalshetty A; Bhattacharjee A; Basu S
Nucl Med Commun; 2020 Oct; 41(10):1095-1099. PubMed ID: 32732598
[TBL] [Abstract][Full Text] [Related]
13. Semiautomatic Tumor Delineation for Evaluation of
Carlsen EA; Johnbeck CB; Loft M; Pfeifer A; Oturai P; Langer SW; Knigge U; Ladefoged CN; Kjaer A
J Nucl Med; 2021 Nov; 62(11):1564-1570. PubMed ID: 33637589
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT.
Ingenerf M; Grawe F; Winkelmann M; Karim H; Ruebenthaler J; Fabritius MP; Ricke J; Seidensticker R; Auernhammer CJ; Zacherl MJ; Seidensticker M; Schmid-Tannwald C
Diagn Interv Imaging; 2024 Jan; 105(1):15-25. PubMed ID: 37453859
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
16. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.
Opalińska M; Morawiec-Sławek K; Kania-Kuc A; Al Maraih I; Sowa-Staszczak A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2022; 13():929391. PubMed ID: 36046793
[TBL] [Abstract][Full Text] [Related]
17. The inferior performance of [
Has Simsek D; Guzel Y; Denizmen D; Sanli Y; Buyukkaya F; Kovan B; Komek H; Isik EG; Ozkan ZG; Kuyumcu S
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):828-840. PubMed ID: 37947850
[TBL] [Abstract][Full Text] [Related]
18.
Carlsen EA; Johnbeck CB; Binderup T; Loft M; Pfeifer A; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2020 Oct; 61(10):1491-1497. PubMed ID: 32111685
[TBL] [Abstract][Full Text] [Related]
19. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
20. The predictive value of pretherapy [
Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]